Kathryn Jean Boor Sells 1,636 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) Director Kathryn Jean Boor sold 1,636 shares of the business's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Sarepta Therapeutics Stock Up 1.5 %

Shares of Sarepta Therapeutics stock traded up $1.89 on Friday, reaching $128.17. The company's stock had a trading volume of 619,477 shares, compared to its average volume of 1,236,602. Sarepta Therapeutics, Inc. has a 52 week low of $85.61 and a 52 week high of $173.25. The firm's fifty day simple moving average is $122.64 and its two-hundred day simple moving average is $131.33. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $12.24 billion, a price-to-earnings ratio of 101.02 and a beta of 0.77.

Analyst Ratings Changes

SRPT has been the topic of several research analyst reports. HC Wainwright reduced their price target on shares of Sarepta Therapeutics from $80.00 to $75.00 and set a "sell" rating on the stock in a research report on Tuesday. Barclays reduced their target price on Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating on the stock in a report on Thursday, August 8th. Needham & Company LLC decreased their target price on Sarepta Therapeutics from $205.00 to $202.00 and set a "buy" rating for the company in a research report on Wednesday, November 27th. Guggenheim lifted their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Finally, Robert W. Baird reduced their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $175.55.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently bought and sold shares of the business. Tidal Investments LLC boosted its holdings in shares of Sarepta Therapeutics by 91.2% during the 3rd quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company's stock valued at $704,000 after acquiring an additional 2,688 shares during the last quarter. World Investment Advisors LLC purchased a new stake in Sarepta Therapeutics in the third quarter worth approximately $2,418,000. Sunbelt Securities Inc. boosted its holdings in Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 232 shares during the last quarter. Geode Capital Management LLC grew its position in Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after purchasing an additional 44,306 shares during the period. Finally, M&T Bank Corp raised its stake in Sarepta Therapeutics by 8.5% during the 3rd quarter. M&T Bank Corp now owns 4,462 shares of the biotechnology company's stock valued at $558,000 after buying an additional 349 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.